Pfizer Inc has submitted knowledge on its COVID-19 vaccine amongst 12- to 15-year olds to Britain’s well being regulator, an organization spokesman stated on Tuesday, paving the best way for its authorization to inoculate youngsters within the nation.
“I can affirm we’ve submitted knowledge on the efficacy of the vaccine in 12 to fifteen years olds for overview by U.Okay. MHRA,” the spokesman informed Reuters by e mail.
The transfer comes a day after U.S. regulators licensed the vaccine made by Pfizer and BioNTech SE to be used in youngsters as younger as 12.
In March, Pfizer and BioNTech stated their COVID-19 vaccine was protected, efficient and produced sturdy antibody responses in 12- to 15-year olds, citing a trial of two,260 adolescents, which resulted in 100% efficacy in stopping the sickness.
Pfizer has stated it expects to have security and efficacy knowledge on the vaccine for youngsters aged 2 to 11 in September, when it plans to ask for that age group to be included within the emergency authorization.
The Telegraph earlier reported that Pfizer had requested Britain’s Medicines and Healthcare merchandise Regulatory Company for approval for the vaccine.